Breath Diagnostics, Inc. was incorporated in 2014 with the focus of developing technologies centered around the early detection of cancers and other diseases by measuring concentrations of rare compounds in breath.

The team and leadership have considerable experience in breath analysis and the cutting-edge technology required in the analysis of breath. This research has been instrumental in the patent and the five patents pending for the technologies and in the publication of eight highly visible peer reviewed articles. The scientific team’s work and experience, coupled with the executive team, make the analysis of breath for the early detection of cancer close to reality.